title: A new benzodiazepine pharmacology.
abstract: Classical benzodiazepine drugs are in wide clinical use as anxiolytics, hypnotics, anticonvulsants, and muscle relaxants. They act by enhancing the gamma-aminobutyric acid(A) (GABA(A)) receptor function in the central nervous system. The pharmacological relevance of the multitude of structurally diverse GABA(A) receptor subtypes has only recently been identified. Based on an in vivo point mutation strategy, alpha(1)-GABA(A) receptors were found to mediate sedation, anterograde amnesia, and part of the seizure protection, whereas alpha(2)-GABA(A) receptors, but not alpha(3)-receptors, mediate anxiolysis. Rational drug targeting to specific receptor subtypes has now become possible. Only restricted neuronal networks will be modulated by the new subtype-selective drugs. Promising new anxiolytics have already been developed. A new pharmacology of the benzodiazepine site is on the horizon.
authors.affiliation: Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. mohler@pharma.unizh.ch
authors.forename: H
authors.initials: H
authors.lastname: Möhler
authors.forename: J M
authors.initials: JM
authors.lastname: Fritschy
authors.forename: U
authors.initials: U
authors.lastname: Rudolph
mesh_terms: D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology*; D006801:Humans; D011963:Receptors, GABA-A / Q000187:drug effects; D013569:Synapses / Q000187:drug effects
chemical_list: D011963:Receptors, GABA-A; D001569:Benzodiazepines